Jun 5 |
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
|
May 29 |
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
|
May 22 |
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
|
May 15 |
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
|
May 15 |
Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript
|
May 14 |
Atea Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
|
May 14 |
Atea Pharmaceuticals GAAP EPS of -$0.75 misses by $0.14
|
May 14 |
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 7 |
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
|
Apr 29 |
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
|